Showing 2291-2300 of 9355 results for "".
- Takeda Reports Positive Phase 3 Results for Oral TYK2 Inhibitor Zasocitinibhttps://practicaldermatology.com/news/takeda-reports-positive-phase-3-results-for-oral-tyk2-inhibitor-zasocitinib/2487546/Takeda announced positive topline results from the Phase 3 LATITUDE Atlas (TAK-279-PsO-3004) trial, a head-to-head study evaluating the investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) against deucravacitinib in adults with moderate-to-severe plaque psoriasis.
- AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Immunology Dealhttps://practicaldermatology.com/news/abbvie-to-acquire-apogee-therapeutics-in-109-billion-immunology-deal/2487547/AbbVie announced a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion, a move the manufacturer said adds to its immunology pipeline and strengthens its presence in inflammatory diseases such as atopi
- Analysis Shows Long-Term Cost Impact of Psoriasis and Psoriatic Arthritishttps://practicaldermatology.com/news/analysis-highlights-long-term-cost-impact-of-psoriasis-and-psoriatic-arthritis/2487486/New research published in Dermatology and Therapy suggests the economic burden associated with psoriasis and psoriatic arthritis extends far beyond the diseases themselves and may reach hundreds of billions of dollars over a lifetime. Psoriatic Disease Comorbidities Drive Signifi
- Oral Nicotinamide Linked to Fewer Skin Cancers and Lower Treatment Costshttps://practicaldermatology.com/news/oral-nicotinamide-linked-to-fewer-skin-cancers-and-lower-treatment-costs/2487444/Oral nicotinamide may offer a cost-effective strategy for preventing keratinocyte carcinoma (KC) in patients at high risk for developing multiple skin cancers, according to a new economic evaluation conducted within the Veterans Health Administration (VHA) published in JAMA Dermatology.<
- FDA Approves EBGLYSS 8-Week Dosings in Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-ebglyss-8-week-dosings-in-atopic-dermatitis/2487424/The US Food and Drug Administration (FDA) has approved an every-8-week maintenance dosing regimen for EBGLYSS® (lebrikizumab-lbkz) in adults and adolescents aged 12 years and older weighing at least 40 kg with moderate-to-severe atopic dermatitis, according to an
- Genital Psoriasis Consensus Offers Age-Specific Roadmap for Clinical Carehttps://practicaldermatology.com/news/genital-psoriasis-consensus-offers-age-specific-roadmap-for-clinical-care/2487330/A new expert consensus manuscript in the American Journal of Clinical Dermatology offered recommendations aimed at improving the diagnosis and management of genital psoriasis, according to a press release from Arcutis. The publication represents the second manuscript, Arcutis said
- Skin Cancer Champions Announces Patient Advocacy Summithttps://practicaldermatology.com/news/skin-cancer-champions-announces-patient-advocacy-summit/2487322/The inaugural Patient Advocacy Summit, hosted by Skin Cancer Champions, will be held on October 30, 2026, at The Fairmont Copley Plaza in Boston, Massachusetts, the organization announced. “The Summit is an important milestone in our mission of providing support, advocacy, and amplifying t
- Swiftscope App Integrates Dermatoscopy With SwiftPro Wart Treatmentshttps://practicaldermatology.com/news/swiftscope-app-integrates-dermatoscopy-with-swiftpro-wart-treatments/2487231/Emblation has launched the Swiftscope app, a new digital imaging platform designed to help clinicians visually monitor treatment progress in patients undergoing SwiftPro microwave therapy for common and plantar warts, according to a news release. The announcement f
- Ultrasound Detects Subclinical Joint and Nail Changes in Pediatric Psoriasishttps://practicaldermatology.com/news/ultrasound-detects-subclinical-joint-and-nail-changes-in-pediatric-psoriasis/2487206/Musculoskeletal ultrasound may help identify early inflammatory changes in children with psoriasis before the onset of clinically apparent arthritis, according to findings from a pilot study evaluating joint, entheseal, and nail abnormalities in pediatric patients.
- Review: Botulinum Toxin Shows Potential in Acne Treatmenthttps://practicaldermatology.com/news/systematic-review-highlights-botulinum-toxins-potential-in-acne-treatment/2487204/Botulinum toxin A may offer a potential adjunctive treatment option for both acne vulgaris and acne scarring, according to a recent systematic review published in the Journal of Drugs in Dermatology. Botulinum Toxin S